Phase 2 HR+/HER2- Breast Cancer Clinical Trials
11 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled9 locationsNCT07288359
Recruiting
Phase 2
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Breast NeoplasmsBreast DiseasesCDK4/6 Inhibitor+3 more
Fujian Cancer Hospital2,000 enrolled2 locationsNCT07581834
Recruiting
Phase 1Phase 2
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
HR+/HER2- Advanced Breast CancerHR+/HER2- Breast Cancer
Avenzo Therapeutics, Inc.380 enrolled14 locationsNCT06998407
Recruiting
Phase 1Phase 2
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
HR+/HER2- Breast Cancer
Faeth Therapeutics32 enrolled3 locationsNCT07558733
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 2
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Breast CancerHR+/HER2- Breast Cancer
Henan Cancer Hospital238 enrolled1 locationNCT06967103
Recruiting
Phase 1Phase 2
Study of AVZO-021 in Patients With Advanced Solid Tumors
Endometrial CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+6 more
Avenzo Therapeutics, Inc.430 enrolled13 locationsNCT05867251
Recruiting
Phase 2
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University35 enrolled3 locationsNCT06874933
Recruiting
Phase 2
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University30 enrolled11 locationsNCT06611813
Recruiting
Phase 2
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
HR+/HER2- Breast Cancer
Henan Cancer Hospital357 enrolled1 locationNCT06860529
Recruiting
Phase 1Phase 2
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Advanced Solid TumorHR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.224 enrolled1 locationNCT04282031